Wockhardt quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	929	738	+25.9%
EBITDA	192	72.0	+166.7%
EBITDA margin	20.7%	9.8%	+10.9 pts
Profit before tax	116	−109	—
Net profit	107	−108	—
EPS	₹6.55	−₹5.53	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	929	965	888	782	738	743	721	809	739	700	701	753	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	31.0	45.0	25.0	21.0	20.0	15.0	8.0	9.0	30.0	54.0	8.0	24.0
	960	1,010	913	803	758	758	729	818	769	754	709	777
	233	177	170	159	168	159	121	182	150	144	160	179
	109	156	161	129	140	148	122	150	153	154	150	105
	−22.0	−15.0	−14.0	−55.0	−44.0	−47.0	19.0	−35.0	10.0	−4.0	−8.0	3.0
	203	187	181	186	171	166	164	161	160	157	152	166
	52.0	50.0	60.0	55.0	48.0	48.0	60.0	73.0	73.0	73.0	77.0	76.0
	55.0	53.0	65.0	53.0	56.0	53.0	55.0	55.0	54.0	58.0	55.0	55.0
	214	235	213	185	231	253	167	241	175	352	210	228
	844	843	836	712	770	780	708	827	775	934	796	812
	192	225	177	178	72.0	64.0	128	110	91.0	−103	37.0	72.0
	137	172	112	125	16.0	11.0	73.0	55.0	37.0	−161	−18.0	17.0
Profit
	116	167	77.0	91.0	−12.0	−22.0	21.0	−9.0	−6.0	−180	−87.0	−35.0
	0.0	22.0	−10.0	0.0	−97.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	116	189	67.0	91.0	−109	−22.0	21.0	−9.0	−6.0	−180	−87.0	−35.0
	7.0	5.0	6.0	3.0	4.0	1.0	1.0	3.0	2.0	2.0	3.0	2.0
	2.0	20.0	0.0	6.0	−5.0	22.0	0.0	4.0	8.0	−5.0	−4.0	36.0
	9.0	25.0	6.0	9.0	−1.0	23.0	1.0	7.0	10.0	−3.0	−1.0	38.0
	107	164	61.0	82.0	−108	−45.0	20.0	−16.0	−16.0	−177	−86.0	−73.0
	107	164	61.0	82.0	−108	−45.0	20.0	−16.0	−16.0	−177	−86.0	−73.0
	14.0	150	28.0	93.0	148	56.0	−70.0	89.0	−3.0	−40.0	67.0	−20.0
	121	314	89.0	175	40.0	11.0	−50.0	73.0	−19.0	−217	−19.0	−93.0
	106	166	59.0	78.0	−90.0	−25.0	14.0	−22.0	−14.0	−169	−83.0	−77.0
	1.0	−2.0	2.0	4.0	−18.0	−20.0	6.0	6.0	−2.0	−8.0	−3.0	4.0
Per share
	₹6.55	₹10.23	₹3.61	₹4.81	−₹5.53	−₹1.57	₹0.91	−₹1.47	−₹0.95	−₹11.64	−₹5.75	−₹5.37
	₹6.55	₹10.22	₹3.61	₹4.81	−₹5.53	−₹1.57	₹0.91	−₹1.47	−₹0.95	−₹11.64	−₹5.75	−₹5.37
Other comprehensive income — detail
	14.0	150	28.0	93.0	148	56.0	—	—	—	—	—	—
	0.0	71.0	−1.0	0.0	−0.2	−4.0	−1.0	0.0	0.0	−10.0	1.0	0.0
	14.0	79.0	29.0	93.0	148	60.0	−69.0	89.0	−3.0	−30.0	66.0	−20.0
	116	287	82.0	163	49.0	11.0	−38.0	59.0	−18.0	−205	−27.0	−95.0
	5.0	27.0	7.0	12.0	−9.0	0.0	−12.0	14.0	−1.0	−12.0	8.0	2.0
Per share — as-filed variants
	₹6.55	₹10.23	₹3.61	₹4.81	−₹5.53	−₹1.57	₹0.91	−₹1.47	−₹0.95	−₹11.64	−₹5.75	−₹5.37
	₹6.55	₹10.22	₹3.61	₹4.81	−₹5.53	−₹1.57	₹0.91	−₹1.47	−₹0.95	−₹11.64	−₹5.75	−₹5.37
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	609	647	571	549	474	483	459	512	426	406	399	466
	65.6%	67.0%	64.3%	70.2%	64.2%	65.0%	63.7%	63.3%	57.6%	58.0%	56.9%	61.9%
Adjusted (ex-exceptional items) — derived
	116	167	77.0	91.0	−12.0	−22.0	21.0	−9.0	−6.0	−180	−87.0	−35.0
	0.0	22.0	−10.0	0.0	−97.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	107	145	70.1	82.0	−11.9	−45.0	20.0	−16.0	−16.0	−177	−86.0	−73.0
	₹6.55	₹9.04	₹4.15	₹4.81	−₹0.61	−₹1.57	₹0.91	−₹1.47	−₹0.95	−₹11.64	−₹5.75	−₹5.37

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

WOCKPHARMA₹1,913.40

Wockhardt Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersBIOCON SYNGENE ASTERDM GLAND PPLPHARMA COHANCE LALPATHLAB NATCOPHARMMcap ₹30,997 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	753.0	701.0	700.0	739.0	809.0	721.0	743.0	738.0	782.0	888.0	965.0	929.0
Other Income	24.0	8.0	54.0	30.0	9.0	8.0	15.0	20.0	21.0	25.0	45.0	31.0
Total Income	777.0	709.0	754.0	769.0	818.0	729.0	758.0	758.0	803.0	913.0	1,010.0	960.0
Expenses
+ Cost of Materials Consumed	179.0	160.0	144.0	150.0	182.0	121.0	159.0	168.0	159.0	170.0	177.0	233.0
+ Purchases of Stock-in-Trade	105.0	150.0	154.0	153.0	150.0	122.0	148.0	140.0	129.0	161.0	156.0	109.0
+ Changes in Inventories	3.0	-8.0	-4.0	10.0	-35.0	19.0	-47.0	-44.0	-55.0	-14.0	-15.0	-22.0
+ Employee Benefit Expense	166.0	152.0	157.0	160.0	161.0	164.0	166.0	171.0	186.0	181.0	187.0	203.0
+ Finance Costs	76.0	77.0	73.0	73.0	73.0	60.0	48.0	48.0	55.0	60.0	50.0	52.0
+ Depreciation & Amortisation	55.0	55.0	58.0	54.0	55.0	55.0	53.0	56.0	53.0	65.0	53.0	55.0
+ Other Expenses	228.0	210.0	352.0	175.0	241.0	167.0	253.0	231.0	185.0	213.0	235.0	214.0
Total Expenses	812.0	796.0	934.0	775.0	827.0	708.0	780.0	770.0	712.0	836.0	843.0	844.0
EBITDA	72.0	37.0	-103.0	91.0	110.0	128.0	64.0	72.0	178.0	177.0	225.0	192.0
EBIT	17.0	-18.0	-161.0	37.0	55.0	73.0	11.0	16.0	125.0	112.0	172.0	137.0
Profit
PBT before Exceptional Items	-35.0	-87.0	-180.0	-6.0	-9.0	21.0	-22.0	-12.0	91.0	77.0	167.0	116.0
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-97.0	0.0	-10.0	22.0	0.0
Pretax Income	-35.0	-87.0	-180.0	-6.0	-9.0	21.0	-22.0	-109.0	91.0	67.0	189.0	116.0
+ Current Tax	2.0	3.0	2.0	2.0	3.0	1.0	1.0	4.0	3.0	6.0	5.0	7.0
+ Deferred Tax	36.0	-4.0	-5.0	8.0	4.0	0.0	22.0	-5.0	6.0	0.0	20.0	2.0
Tax Expense	38.0	-1.0	-3.0	10.0	7.0	1.0	23.0	-1.0	9.0	6.0	25.0	9.0
Net Income	-73.0	-86.0	-177.0	-16.0	-16.0	20.0	-45.0	-108.0	82.0	61.0	164.0	107.0
+ Net Income — Continuing Ops	-73.0	-86.0	-177.0	-16.0	-16.0	20.0	-45.0	-108.0	82.0	61.0	164.0	107.0
+ Other Comprehensive Income	-20.0	67.0	-40.0	-3.0	89.0	-70.0	56.0	148.0	93.0	28.0	150.0	14.0
Total Comprehensive Income	-93.0	-19.0	-217.0	-19.0	73.0	-50.0	11.0	40.0	175.0	89.0	314.0	121.0
Net Income to Common	-77.0	-83.0	-169.0	-14.0	-22.0	14.0	-25.0	-90.0	78.0	59.0	166.0	106.0
Minority Interest	4.0	-3.0	-8.0	-2.0	6.0	6.0	-20.0	-18.0	4.0	2.0	-2.0	1.0
Per Share
Basic EPS	-5.37	-5.75	-11.64	-0.95	-1.47	0.91	-1.57	-5.53	4.81	3.61	10.23	6.55
Diluted EPS	-5.37	-5.75	-11.64	-0.95	-1.47	0.91	-1.57	-5.53	4.81	3.61	10.22	6.55
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	56.0	148.0	93.0	28.0	150.0	14.0
+ Items NOT to be Reclassified to P&L	0.0	1.0	-10.0	0.0	0.0	-1.0	-4.0	-0.2	0.0	-1.0	71.0	0.0
+ Items to be Reclassified to P&L	-20.0	66.0	-30.0	-3.0	89.0	-69.0	60.0	148.2	93.0	29.0	79.0	14.0
Comprehensive Income — Owners of Parent	-95.0	-27.0	-205.0	-18.0	59.0	-38.0	11.0	49.0	163.0	82.0	287.0	116.0
Comprehensive Income — Non-controlling Interests	2.0	8.0	-12.0	-1.0	14.0	-12.0	0.0	-9.0	12.0	7.0	27.0	5.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	-5.37	-5.75	-11.64	-0.95	-1.47	0.91	-1.57	-5.53	4.81	3.61	10.23	6.55
Diluted EPS — Continuing Operations	-5.37	-5.75	-11.64	-0.95	-1.47	0.91	-1.57	-5.53	4.81	3.61	10.22	6.55
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	466.0	399.0	406.0	426.0	512.0	459.0	483.0	474.0	549.0	571.0	647.0	609.0
Gross Margin %	61.89	56.92	58.00	57.65	63.29	63.66	65.01	64.23	70.20	64.30	67.05	65.55
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-35.0	-87.0	-180.0	-6.0	-9.0	21.0	-22.0	-12.0	91.0	77.0	167.0	116.0
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-97.0	0.0	-10.0	22.0	0.0
Net Income Adj (tax-effected)	-73.0	-86.0	-177.0	-16.0	-16.0	20.0	-45.0	-11.9	82.0	70.1	144.9	107.0
EPS Adj	-5.37	-5.75	-11.64	-0.95	-1.47	0.91	-1.57	-0.61	4.81	4.15	9.04	6.55
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Paid Up Equity Capital	72.0	72.0	77.0	77.0	77.0	81.0	81.0	81.0	81.0	81.0	81.0	81.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Wockhardt Q2 FY27 results date

Wockhardt (NSE: WOCKPHARMA) will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, according to the board-meeting notice it filed on 27 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹106 crore, against a loss of ₹90 crore in Q1 FY26 and down 36.1% from ₹166 crore in Q4 FY26. Revenue from operations was ₹929 crore, up 25.9% year on year and down 3.7% from the previous quarter.

Board-meeting notice filed: 27 October 2026
Q2 FY26 results (a year earlier): 3 November 2025
Q1 FY27 results (the latest): 10 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 2 November 2026Monday · notice filed 27 Oct
Q1 FY27 net profit: ₹106 Crloss ₹90 Cr in Q1 FY26−36.1% vs Q4 FY26
Q1 FY27 revenue: ₹929 Cr+25.9% vs Q1 FY26−3.7% vs Q4 FY26
Q1 FY27 operating margin: 14.7%+12.6 pts vs Q1 FY26−3.1 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹78 CrRevenue ₹782 Cr
Q1 FY27 EPS (basic): ₹6.55

Questions

When will Wockhardt announce its Q2 FY27 results?

On 2 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 27 October 2026). Last year it reported Q2 FY26 on 3 November 2025.

What will Wockhardt's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹78 crore and revenue from operations ₹782 crore. The latest quarter, Q1 FY27, had a net profit of ₹106 crore and revenue of ₹929 crore.

What were Wockhardt's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹106 crore, against a loss of ₹90 crore in Q1 FY26 and down 36.1% from ₹166 crore in Q4 FY26. Revenue from operations was ₹929 crore, up 25.9% year on year and down 3.7% from the previous quarter.

How has Wockhardt's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹78 crore in Q2 FY26, ₹59 crore in Q3 FY26, ₹166 crore in Q4 FY26 and ₹106 crore in Q1 FY27. That is ₹409 crore over the four quarters. Revenue from operations: ₹782 crore, ₹888 crore, ₹965 crore and ₹929 crore.

What was Wockhardt's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹213 crore in FY26 (April 2025–March 2026), against a loss of ₹47 crore in FY25. It was a loss of ₹463 crore in FY24 and a loss of ₹559 crore in FY23.

What was Wockhardt's revenue in FY26?

Revenue from operations was ₹3,373 crore in FY26 (April 2025–March 2026), up 12.0% from ₹3,012 crore in FY25. It was ₹2,798 crore in FY24 and ₹2,651 crore in FY23: up 27.2% over three years, 8.4% a year on average.

Where do these Wockhardt figures come from?

From Wockhardt's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.